We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sets Rules for Using Blood Plasma in and Outside COVID-19 Trials
FDA Sets Rules for Using Blood Plasma in and Outside COVID-19 Trials
Researchers planning trials on the use of convalescent blood plasma to treat COVID-19 must submit an investigational new drug (IND) application, according to a new FDA final guidance that will remain in effect only for the duration of the public health emergency.